ArticleScientific reports2014
Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Antitumor Effects and the Potential Mechanism of 10-HDA against SU-DHL-2 Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- IL-17A Orchestrates Reactive Oxygen Species/HIF1α-Mediated Metabolic Reprogramming in Psoriasis.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- A large-scale targeted proteomics of serum and tissue shows the utility of classifying high grade and low grade meningioma tumors.Clinical proteomics · 2023Article
- Proteomic Analysis on Sequential Samples of Cystic Fluid Obtained from Human Brain Tumors.Cancers · 2023Article
- Multiple Adaptive Strategies of HimalayanFrontiers in microbiology · 2022Article
- Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers.International journal of molecular sciences · 2021Review
- Article
- Multiple Reaction Monitoring-Based Targeted Assays for the Validation of Protein Biomarkers in Brain Tumors.Frontiers in oncology · 2021Article
- Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies.Oncotarget · 2020Article
- Identification of host factors limiting the overexpression of recombinant Cu, Zn superoxide dismutase in Escherichia coli.Biotechnology letters · 2020Article
- Proteomics pinpoints alterations in grade I meningiomas of male versus female patients.Scientific reports · 2020Article
- An Integrated Quantitative Proteomics Workflow for Cancer Biomarker Discovery and Validation in Plasma.Frontiers in oncology · 2020Article
- Article
- Comprehending Meningioma Signaling Cascades Using Multipronged Proteomics Approaches & Targeted Validation of Potential Markers.Frontiers in oncology · 2020Article
- Article
- Article
- Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation.Frontiers in oncology · 2019Article
- An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.Scientific reports · 2018Article
- Evaluation of autoantibody signatures in meningioma patients using human proteome arrays.Oncotarget · 2017Article
- Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are the most common non-glial tumors of the brain and spine. Pathophysiology and definite histological grading of meningiomas are frequently found to be deceptive due to their unusual morphological features and locations. Here for the first time we report a comprehensive serum proteomic analysis of different grades of meningiomas by using multiple quantitative proteomic and immunoassay-based approaches to obtain mechanistic insights about disease pathogenesis and identify grade specific protein signatures. In silico functional analysis revealed modulation of different vital physiological pathways including complement and coagulation cascades, metabolism of lipids and lipoproteins, immune signaling, cell growth and apoptosis and integrin signaling in meningiomas. ROC curve analysis demonstrated apolipoprotein E and A-I and hemopexin as efficient predictors for meningiomas. Identified proteins like vimentin, alpha-2-macroglobulin, apolipoprotein B and A-I and antithrombin-III, which exhibited a sequential increase in different malignancy grades of meningiomas, could serve as potential predictive markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.